Abstract| Volume 18, ISSUE 6, SUPPLEMENT , S10, June 2016

A Phase III Clinical Trial of a Cell and Gene Therapy, Invossa™, for the Treatment of Osteoarthritis

      Invossa™ (project name: TissueGene-C) is a cell and gene therapy for the treatment of osteoarthritis that contains non-transformed chondrocytes and transduced chondrocytes by the ratio of 3:1. The transduced cell employs ex-vivo gene delivery via a retroviral transduction which makes overexpression of transforming growth factor β1 (TGF β1).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect